Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis

Journal of Medical Microbiology

Volumn 53, Issue 8, 2004, Pages 769-773

  Wade, Mary Margaret ^a   Zhang, Ying ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DICYCLOHEXYLCARBODIIMIDE; ADENOSINE TRIPHOSPHATASE INHIBITOR; DICYCLOHEXYLCARBODIIMIDE; ENZYME INHIBITOR; ISONIAZID; OXYGEN; PYRAZINAMIDE; PYRAZINOIC ACID; RIFAMPICIN; ROTENONE; SODIUM AZIDE; SODIUM NITRATE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; DRUG DERIVATIVE; NITRATE; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; ANAEROBIC GROWTH; BACTERIAL COUNT; ELECTRON TRANSPORT; ENERGY METABOLISM; GROWTH, DEVELOPMENT AND AGING; METABOLISM;

ADENOSINE TRIPHOSPHATASES; ANAEROBIOSIS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; ELECTRON TRANSPORT; ENERGY METABOLISM; ENZYME INHIBITORS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; NITRATES; OXYGEN; PYRAZINAMIDE; RIFAMPIN;

EID: 4344678279     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.45639-0     Document Type: Article

References (14)

1. Aisen, P. (1980). The transferrins. In Iron in Biochemistry and Medicine, pp. 87-123. Edited by A. Jacobs & M. Worwood. London, UK: Academic Press.
2. Canetti, G. (1955). The Tubercle Bacillus in the Pulmonary Lesion of Man. New York: Springer.
3. Cole, S. T., Brosch, R., Parkhill, J. & 39 other authors. (1998). Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544.
4. Heifets, L. & Lindholm-Levy, P. (1992). Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145, 1223-1225.
5. McDermott, W. & Tompsett, R. (1954). Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 70, 748-754.
6. Mitchison, D. (1985). The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219-225.
7. Somoskovi, A., Wade, M. M., Sun, Z. & Zhang, Y. (2004). Iron enhances the antituberculous activity of pyrazinamide. J Antimicrob Chemother 53, 192-196.
8. Tarshis, M. S. & Weed, W. A., Jr (1953). Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc 67, 391-395.
9. Wayne, L. G. & Hayes, L. G. (1996). An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64, 2062-2069.
10. Zhang, Y. & Telenti, A. (2000). Genetics of drug resistance in Mycobacterium tuberculosis. In Molecular Genetics of Mycobacteria, pp. 235-254, Edited by G. Hatfull & W. R. Jacobs Jr. Washington, DC: ASM Press.
11. Zhang, Y. & Mitchison, D. A. (2003). The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7, 6-21.
12. Zhang, Y., Scorpio, A., Nikaido, H. & Sun, Z. H. (1999). Role of acid pH and deficient efflux of pyrazinoic acid in the unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 181, 2044-2049.
13. Zhang, Y., Permar, S. & Sun, Z. (2002). Conditions that may affect the results of Mycobacterium tuberculosis susceptibility testing to pyrazinamide. J Med Microbiol 51, 42-49.
14. Zhang, Y., Wade, M. M., Scorpio, A., Zhang, H. & Sun, Z. (2003). Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52, 790-795.